Jae Mo Park1, Sonal Josan1,2, Taichang Jang3, Milton Merchant3, Ron Watkins1, Ralph E Hurd4, Lawrence D Recht3, Dirk Mayer2,5, Daniel M Spielman1. 1. Department of Radiology, Stanford University, Stanford, California, USA. 2. SRI International, Menlo Park, California, USA. 3. Department of Neurology and Neurological Sciences, Stanford, California, USA. 4. Applied Science Laboratory, GE Healthcare, Menlo Park, California, USA. 5. Diagnostic Radiology and Nuclear Medicine, University of Maryland, Baltimore, Maryland, USA.
Abstract
PURPOSE: MRS of hyperpolarized [2-(13)C]pyruvate can be used to assess multiple metabolic pathways within mitochondria as the (13)C label is not lost with the conversion of pyruvate to acetyl-CoA. This study presents the first MR spectroscopic imaging of hyperpolarized [2-(13)C]pyruvate in glioma-bearing brain. METHODS: Spiral chemical shift imaging with spectrally undersampling scheme (1042 Hz) and a hard-pulse excitation was exploited to simultaneously image [2-(13)C]pyruvate, [2-(13)C]lactate, and [5-(13)C]glutamate, the metabolites known to be produced in brain after an injection of hyperpolarized [2-(13)C]pyruvate, without chemical shift displacement artifacts. A separate undersampling scheme (890 Hz) was also used to image [1-(13)C]acetyl-carnitine. Healthy and C6 glioma-implanted rat brains were imaged at baseline and after dichloroacetate administration, a drug that modulates pyruvate dehydrogenase kinase activity. RESULTS: The baseline metabolite maps showed higher lactate and lower glutamate in tumor as compared to normal-appearing brain. Dichloroacetate led to an increase in glutamate in both tumor and normal-appearing brain. Dichloroacetate-induced %-decrease of lactate/glutamate was comparable to the lactate/bicarbonate decrease from hyperpolarized [1-(13)C]pyruvate studies. Acetyl-carnitine was observed in the muscle/fat tissue surrounding the brain. CONCLUSION: Robust volumetric imaging with hyperpolarized [2-(13)C]pyruvate and downstream products was performed in glioma-bearing rat brains, demonstrating changes in mitochondrial metabolism with dichloroacetate.
PURPOSE: MRS of hyperpolarized [2-(13)C]pyruvate can be used to assess multiple metabolic pathways within mitochondria as the (13)C label is not lost with the conversion of pyruvate to acetyl-CoA. This study presents the first MR spectroscopic imaging of hyperpolarized [2-(13)C]pyruvate in glioma-bearing brain. METHODS: Spiral chemical shift imaging with spectrally undersampling scheme (1042 Hz) and a hard-pulse excitation was exploited to simultaneously image [2-(13)C]pyruvate, [2-(13)C]lactate, and [5-(13)C]glutamate, the metabolites known to be produced in brain after an injection of hyperpolarized [2-(13)C]pyruvate, without chemical shift displacement artifacts. A separate undersampling scheme (890 Hz) was also used to image [1-(13)C]acetyl-carnitine. Healthy and C6 glioma-implanted rat brains were imaged at baseline and after dichloroacetate administration, a drug that modulates pyruvate dehydrogenase kinase activity. RESULTS: The baseline metabolite maps showed higher lactate and lower glutamate in tumor as compared to normal-appearing brain. Dichloroacetate led to an increase in glutamate in both tumor and normal-appearing brain. Dichloroacetate-induced %-decrease of lactate/glutamate was comparable to the lactate/bicarbonate decrease from hyperpolarized [1-(13)C]pyruvate studies. Acetyl-carnitine was observed in the muscle/fat tissue surrounding the brain. CONCLUSION: Robust volumetric imaging with hyperpolarized [2-(13)C]pyruvate and downstream products was performed in glioma-bearing rat brains, demonstrating changes in mitochondrial metabolism with dichloroacetate.
Authors: Jan H Ardenkjaer-Larsen; Björn Fridlund; Andreas Gram; Georg Hansson; Lennart Hansson; Mathilde H Lerche; Rolf Servin; Mikkel Thaning; Klaes Golman Journal: Proc Natl Acad Sci U S A Date: 2003-08-20 Impact factor: 11.205
Authors: Eugene Milshteyn; Cornelius von Morze; Galen D Reed; Hong Shang; Peter J Shin; Zihan Zhu; Hsin-Yu Chen; Robert Bok; Andrei Goga; John Kurhanewicz; Peder E Z Larson; Daniel B Vigneron Journal: Magn Reson Imaging Date: 2017-01-07 Impact factor: 2.546
Authors: Sarmad Siddiqui; Stephen Kadlecek; Mehrdad Pourfathi; Yi Xin; William Mannherz; Hooman Hamedani; Nicholas Drachman; Kai Ruppert; Justin Clapp; Rahim Rizi Journal: Adv Drug Deliv Rev Date: 2016-09-04 Impact factor: 15.470
Authors: Donghyun Hong; Georgios Batsios; Pavithra Viswanath; Anne Marie Gillespie; Manushka Vaidya; Peder E Z Larson; Sabrina M Ronen Journal: Magn Reson Med Date: 2021-11-14 Impact factor: 4.668
Authors: Jeremy W Gordon; Adam W Autry; Shuyu Tang; Jasmine Y Graham; Robert A Bok; Xucheng Zhu; Javier E Villanueva-Meyer; Yan Li; Michael A Ohilger; Maria Roselle Abraham; Duan Xu; Daniel B Vigneron; Peder E Z Larson Journal: Magn Reson Med Date: 2020-07-22 Impact factor: 4.668
Authors: Sangmoo Jeong; Angela Maria Savino; Rachel Chirayil; Ersilia Barin; Yuanming Cheng; Sun-Mi Park; Alexandra Schurer; Edouard Mullarky; Lewis C Cantley; Michael G Kharas; Kayvan R Keshari Journal: Cell Metab Date: 2020-12-22 Impact factor: 27.287
Authors: Cornelius von Morze; John A Engelbach; Galen D Reed; Albert P Chen; James D Quirk; Tyler Blazey; Rohit Mahar; Craig R Malloy; Joel R Garbow; Matthew E Merritt Journal: Magn Reson Med Date: 2020-11-12 Impact factor: 4.668